north40000, we deliver Cotara via a convection-enhanced delivery which uses a catheter to bypass the blood brain barrier.
Cotara is delivered through a special method called convection-enhanced delivery (CED). CED uses a catheter to bypass the blood brain barrier and target the specific tumor site in the brain, directing Cotara to the tumor more precisely. This type of delivery has been shown to achieve up to a 10,000-fold greater concentration in local therapy exposure than conventional intravenous drug administration, while minimizing unwanted exposure. http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=266069 I guess answering a question now on what is a good buying point is considered OT now? I bet if the reply was "Buy all you can now" the answer would have remained.
Dr. Boockvar, the doctor interviewed in the NYTimes article I posted yesterday, was also interviewed on CNBC this morning (~6:50 am). I have the impression from what he said that he is definitely looking for a second drug to administer via the micro- catheter delivery system he used with Avastin. Recall that the NYTimes article also said:
>>The study, which began in August, is still in its earliest phase, meaning its main goal is to measure safety, not efficacy — to find out if it is safe to spray Avastin directly into brain arteries and at what dose. Nonetheless, the doctors were pleased when M.R.I. scans of the first few patients showed that the treatment seemed to erase any sign of recurring glioblastomas. But how long the effect will last remains to be seen.<<
I gather that Cotara is under similar studies in India and the U.S. to determine its safety and efficacy when administered via catheter for treatment of glioblastoma. See entdoc's and jessme's replies to the above post, particularly:
Market Data 
Markets 
AI
